Advanced search
Publication Cover
Acta Oncologica Volume 60, 2021 - Issue 2
Journal homepage
699
Views
0
CrossRef citations to date
0
Altmetric
LETTERS TO THE EDITOR: CLINICAL ONCOLOGY

Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort

Irina Tsibulaka Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaORCID Iconhttps://orcid.org/0000-0001-6795-3015View further author information
ORCID Icon,
Verena Wiesera Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaView further author information
,
Hannah Welponera Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaView further author information
,
Katharina Leitnera Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaView further author information
,
Hubert Hacklb Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, AustriaView further author information
,
Christian Martha Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaView further author information
,
Heidelinde Fiegla Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaCorrespondence[email protected] [email protected]
View further author information
&
Alain G. Zeimeta Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, AustriaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 187-190 | Received 20 Apr 2020, Accepted 19 Oct 2020, Published online: 04 Nov 2020

References

  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
  • Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.
  • Jóhannsson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998;16:397–404.
  • Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–710.
  • Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–437.
  • Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27:1449–1455.
  • Harter P, Johnson T, Berton-Rigaud D, et al. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol. 2016;140:443–449.
  • Ledermann JA. PARP inhibitors in ovarian cancer. Ann oncol. 2016;27:i40–i44.
  • Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263–272.
  • Tsibulak I, Wieser V, Degasper C, et al. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br J Cancer. 2018;119:683–692.
  • Goebel G, Berger R, Strasak AM, et al. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br J Cancer. 2012;106:189–198.
  • Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35.
  • Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
  • Wang Z, Zhang J, Zhang Y, et al. Expression and mutations of BRCA in breast cancer and ovarian cancer: evidence from bioinformatics analyses. Int J Mol Med. 2018;42:3542–3550.
  • Egawa C, Miyoshi Y, Takamura Y, et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer. 2001;95:255–259.
  • Egawa C, Miyoshi Y, Taguchi T, et al. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Int J Cancer. 2002;98:879–882.
  • Hossain MA, Saiful Islam SM, Quinn JMW, et al. Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality. J Biomed Inform. 2019;100:103313.
  • Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482–490.
  • Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382–390.
  • Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164.
  • González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
  • Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.